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Objective
Systemic-onset JIA (so-JIA) is often persisting into
adulthood and can be refractory to treatment including
biologicals. We report on efficacy and safety of Tocilizu-
mab in adults with persistent active so-JIA in a retro-
spective single center descriptive cohort study.
Patients and methods
Disease activity scores (DAS-CRP), ESR and CRP were
measured just before and at 1- 6- and 12 months of
Tocilizumab treatment in all adults with refractory so-
JIA at our University Hospital. Adverse events were
recorded.
Results
Eight patients (5 women, 3 men) with a median age of
27,5yr and median disease duration of 16 yr were trea-
ted. All previously failed Methotrexate, other classical
DMARD’s, 7/8 also failed on one or more biologicals
(mostly TNF blockers, Anakinra in 1). Median HAQ
before starting Tocilizumab was 1.25 (0.75-2.13). Tocili-
zumab dose was 8mg/kg/month, except for 1 patient
receiving 6mg/kg/2 weeks. The median DAS-CRP
decreased from 5,10(1.6-5.3) (n=6) at start to 2,25(1.3-
2.9) (n=6) after six months (p=0,046). At 12 months,
median DAS-CRP was 1,9(1.5-6.1)(n=3). Median ESR/
CRP decreased from 35(15-87)(n=6)/69,2(9.1-292.6)mg/l
(n=8) at start to
2(1-7)/1,2(0.6-1.4)mg/l(n=7) at six months (p=0,028/
0,018). At 1 year median ESR/CRP were 3,5(1-13)(n=4)/
0,6(0.6-23.1)mg/l(n=5). A decrease/complete stop of
steroids was observed in 6 patients. Atypical rash was
seen in one patient, EBV-induced MAS occurred in 1
patient after 7 yrs of Tocilizumab.
Conclusion
Our report on young adults with persistingly active so-
JIA treated with Tocilizumab shows a fast, steep and
persistent decrease in disease activity up to at least 1
year, demonstrating the efficacy of IL6-receptor antag-
onism also in patients with long-standing refractory so-
JIA.
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